Barclays PLC Bicycle Therapeutics PLC Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Barclays PLC holds 2,612 shares of BCYC stock, worth $27,347. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,612
Previous 267
878.28%
Holding current value
$27,347
Previous $6,000
516.67%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding BCYC
# of Institutions
104Shares Held
42.9MCall Options Held
12.1KPut Options Held
17.4K-
Baker Bros. Advisors LP New York, NY10.9MShares$114 Million1.69% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.55MShares$47.7 Million0.15% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.45MShares$36.1 Million8.16% of portfolio
-
Westfield Capital Management CO LP Boston, MA2.61MShares$27.3 Million0.17% of portfolio
-
Armistice Capital, LLC New York, NY2.2MShares$23 Million0.43% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $311M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...